References
- American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–1131.
- Ornaghi S, Paidas MJ. Upcoming drugs for the treatment of preeclampsia in pregnant women. Expert Rev Clin Pharmacol. 2014;7:599–603.
- Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61:932–942.
- Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–192.
- Costantine MM, Cleary K, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high risk pregnant women. Obstet Gynecol. 2013;121:349–353.
- Ananth CV. Ischemic placental disease: a unifying concept for preeclampsia, intrauterine growth restriction, and placental abruption. Semin Perinatol. 2014;38:131–132.
- Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009 Mar;30(Suppl):S32–7.
- Cudmore M, Ahmad S, Al-Ani B, et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007;115:1789–1797.
- Tong S, Kaitu’u-Lino TJ, Onda K, et al. Heme oxygenase-1 is not decreased in preeclamptic placenta and does not negatively regulate placental soluble fms-like tyrosine kinase-1 or soluble endoglin secretion. Hypertension. 2015;66:1073–1081.
- Barton JR, Sibai B. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112:359–372.
- Askie LM, Duley L, Henderson-Smart DJ, et al.; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791–1798.
- Costantine M, Tamayo E, Bytautiene E, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol. 2010;116(1):114–120.
- Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA. 2011;108:1451–1455.
- Brownfoot FC, Tong S, Hannan NJ, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66:687–697.
- Costantine MM, Cleary K, Hebert M, et al.; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):720.e1–720.e17.
- Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000;39:397–412.
- Nanovskaya TN, Patrikeeva SL, Paul J, et al. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013;209:373.e1–5.
- Kazmin A, Garcia-Bournissen F, Koren G. Risk of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can. 2007;29(11):9.